Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Advances AMT Geophysical Survey Identifying Additional Drill Targets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Ionis Pharmaceuticals Inc IONS

Healthcare Biotechnology
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IONS)

DAWNZERA(TM) (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Business Wire 1 day ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

GlobeNewswire 10 days ago

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

Business Wire 10 days ago

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Business Wire January 7, 2026

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2026

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Business Wire December 2, 2025

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

Business Wire December 1, 2025

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

GlobeNewswire November 17, 2025

Biogen Completes Acquisition of Alcyone Therapeutics

GlobeNewswire November 14, 2025
View More News ››

Opinion & Analysis (NDAQ:IONS)

Small-Cap Growth ETFs Restore Leadership Role

Benzinga.com  March 19, 2015

Biotech Stocks Sell Off, ETFs Fall Over 5%

Benzinga.com  December 23, 2014

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Turkey ETF in Focus on Political Worries - ETF News And Commentary

Benzinga.com  July 16, 2014

Will Gold ETFs Continue To Shine? - ETF News And Commentary

Benzinga.com  June 18, 2014
View More Opinion ››

Bullboard Posts (NDAQ:IONS)

VP exercised options

A vice president of Isis Pharmaceuticals Inc. exercised options for 12,200 shares of common stock and sold them under a prearranged...
mart33 - April 10, 2008

news and potential uptrend

 Isis Pharmaceuticals last week reported a sharp drop in its net loss for 2007 despite higher operating expenses as the company...
mart33 - March 24, 2008

Overview of the stock

Here are some points to consider:1) Biotech industry is very volatile though ISIS stock prices started accelerating upwards in August and...
bearsko - February 25, 2008

isis needs a kiss of life

Maybe Tobin is the volunteer...trading on the 27th April,07 @ $10.22
kungfu010 - April 27, 2007

Tobin Smith is pumping ISIS presently

Wow, I can't believe that no one has left a message on this board since 2003. Toby Smith (Tobin) is calling this one a major buy-out...
Silver_Is_Money - February 4, 2007

$12.50 Option

Anybody who bought the April $12.50 Call option for $1.75 is shot. Porter Stansberry recommended this stock for a big move with Phase...
layman34 - February 11, 2003
View more Bullboard ››

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »

Podcasts